Mitomycin Dosage
This dosage information may not include all the information needed to use Mitomycin safely and effectively. See additional information for Mitomycin.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Stomach Cancer
For use in treatment of disseminated adenocarcinoma of the stomach in proven combination with other approved chemotherapeutic agents or as palliative treatment when other modalities have failed:
After full hematologic recovery from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m2 intravenously as a single dose via a functioning intravenous catheter.
Usual Adult Dose for Pancreatic Cancer
For use in treatment of disseminated adenocarcinoma of the pancreas in proven combination with other approved chemotherapeutic agents or as palliative treatment when other modalities have failed:
After full hematologic recovery from any previous chemotherapy, the following dosage schedule may be used at 6 to 8 week intervals: 20 mg/m2 intravenously as a single dose via a functioning intravenous catheter.
Usual Adult Dose for Bladder Cancer
40 mg by intravesical installation
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
If the nadir after the previous dose includes a leukocyte count of 2,000 to 2,999/mm3 or platelet count of 25,000 to 74,999/mm3, then 70% of the prior dose should be given as the next dose.
If the nadir after the previous dose includes a leukocyte count of <2,000/mm3 or platelet count of <25,000/mm3, then 50% of the prior dose should be given as the next dose.
No repeat dosage should be given until the leukocyte count has returned to 4,000/mm3 and platelet count to 100,000/mm3
When mitomycin is used in combination with other myelosuppressive agents, the doses should be adjusted accordingly.
Precautions
Extreme care to avoid extravasation is recommended.
Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).
Dialysis
Data not available
Other Comments
If the disease continues to progress after two courses of mitomycin, the drug should be stopped since the chances of response are minimal.
